Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant MPDL3280A versus observation in high-risk muscle-invasive bladder cancer after cystectomy
2014-005603-25Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in muscle-invasive bladder cancer (MIBC), bladder cancer and transitional cell carcinoma of the bladder (TCC) comparing Atezolizumab adjuvant arm with Observation arm (2 arms). Primary endpoint: Investigator-assessed disease-free survival (DFS). Started Jun 2015; status: active.
02
Drugs
atezolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2014-005603-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005603-25.